arrow
M

Matthew B. Rettig

university of california
H指数:58
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Recurrent prostate adenocarcinoma after radical prostatectomy: Principles of multidisciplinary management across a spectrum of disease

根治性前列腺切除术后的复发性前列腺腺癌:不同疾病阶段的多学科管理原则

2026-09-290
OAAI
Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis

不良病理特征对术后放疗联合激素治疗在复发性前列腺癌中潜在获益的影响:一项个体患者数据Meta分析

2026-07-280
PRE
PCAMEX: A MIXTURE-OF-EXPERTS AI FRAMEWORK FOR WHOLE-SLIDE PROSTATE CANCER PATHOLOGY DIAGNOSIS IN VETERANS

PCAMEX:一种用于退伍军人全切片前列腺癌病理诊断的混合专家AI框架

2026-05-010
PRE
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis

激素疗法的使用与持续时间联合术后放疗治疗复发性前列腺癌:一项个体患者数据Meta分析

2026-02-260
OAAI
Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study

将基线PSMA PET衍生参数与接受[177Lu]Lu-PSMA-617治疗患者的毒副作用、不良事件、疼痛及生活质量相关联:一项单中心回顾性研究

2026-02-010
PRE
Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy

经前列腺特异性膜抗原 PET/CT 引导的根治性前列腺切除术后挽救性放疗的五年结果

2026-02-012
PRE
Clinical Impact of Changes in Tumor Uptake and Volume on PSMA PET/CT During [177Lu]Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer

转移性去势抵抗性前列腺癌在[177Lu]Lu-PSMA治疗期间,肿瘤摄取和体积变化对PSMA PET/CT的临床影响

2026-01-010
PRE
Stereotactic Intensity-modulated Radiotherapy After Radical Prostatectomy (SCIMITAR): 4-Year Outcomes of a Phase 2 Clinical Trial

立体定向调强放疗在根治性前列腺切除术后的应用(SCIMITAR):一项II期临床试验的4年结果

2025-09-300
PRE
Genomic and Transcriptomic Profiling of Radiation Resistant, Locally Recurrent Prostate Cancer

辐射抵抗性局部复发前列腺癌的基因组与转录组分析

2025-09-290
PRE
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer

转录谱阐明了致死性前列腺癌中恩扎鲁他胺极端无反应的程序

2025-07-070
OAAI
Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen–defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy

SOLAR和SATURN临床试验的合并分析:比较系统性治疗和肿瘤定向治疗后,同步与异时性前列腺特异性膜抗原定义的寡转移性前列腺癌的进展情况

2025-06-010
PRE
Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy A Nonrandomized Clinical Trial

根治性前列腺切除术后立体定向调强放疗的患者报告结果非随机临床试验

2025-05-151
PRE
Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study

CRPC患者接受雄激素受体信号抑制剂治疗后PSMA PET表达的早期变化:一项国际多中心回顾性研究

2025-03-260
PRE
Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study

转移性激素敏感前列腺癌中的低容量和高容量疾病:从CHAARTED到PSMA PET—一项国际多中心回顾性研究

2025-01-033
PRE
Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium

雄激素抑制和前列腺放疗后的睾酮恢复 (TRANSPORT): 来自前列腺癌随机试验荟萃分析 (MARCAP) 联盟的五个随机试验的汇总分析

2025-01-011
PRE
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

对患有生物化学复发和晚期前列腺癌的男性实施循证策略: 来自美国前列腺癌会议2024的共识建议

CANCER
IF5.1
2024-12-010
PRE